A pharmacogenomic approach to Alzheimer's disease

Acta Neurologica Scandinavica, Supplement

Volumn 102, Issue 176, 2000, Pages 12-19

  Cacabelos, R ^a   Alvarez, A ^a   Fenandez Novoa, L ^a   Lombardi, V R M ^a  

^a Centro de Investigacion Biomedica EuroEspes   (Spain)

Author keywords

AD related genes; Alzheimer's disease; Anapsos calagualine; CDP choline; Multifactorial therapy; Mutational genetics; Pharmacogenomics; Piracetam; Susceptibility genetics

Indexed keywords

CITICOLINE; PIRACETAM; POLYPODIUM LEUCOTOMOS EXTRACT; APOLIPOPROTEIN E; GLYCOSIDE; IMMUNOLOGICAL ADJUVANT; MEMBRANE PROTEIN; NOOTROPIC AGENT; PRESENILIN 1; PRESENILIN 2; PSEN1 PROTEIN, HUMAN; PSEN2 PROTEIN, HUMAN;

ADULT; ALLELISM; ALZHEIMER DISEASE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DNA POLYMORPHISM; DRUG EFFICACY; DRUG RESPONSE; EXON; FEMALE; GENE FREQUENCY; GENETIC MODEL; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL PERFORMANCE; PATHOGENESIS; PHARMACOGENOMICS; POINT MUTATION; PREDICTION; PROGNOSIS; AGED; COGNITION; DRUG COMBINATION; DRUG EFFECT; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; TREATMENT OUTCOME;

ADJUVANTS, IMMUNOLOGIC; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; APOLIPOPROTEINS E; COGNITION; CYTIDINE DIPHOSPHATE CHOLINE; DRUG THERAPY, COMBINATION; EXONS; FEMALE; GENOTYPE; GLYCOSIDES; HUMANS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; NOOTROPIC AGENTS; PIRACETAM; PRESENILIN-1; PRESENILIN-2; PROGNOSIS; TREATMENT OUTCOME;

EID: 0034572814     PISSN: 00651427     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Neurogeriatrics
2. The glutamatergic system and neurodegeneration in dementia: Preventive strategies in Alzheimer disease
3. Phosphorylation of tau, Aβ-formation, and apoptosis after in vivo inhibition of PP-1 and PP-2A
4. Tau protein pathology in neurodegenerative diseases
5. Pharmacological treatment of Alzheimer's disease. From psychotropic drugs and cholinesterase inhibitors to pharmacogenomics
6. Genetic classification of primary degenerative disease
7. Alzheimer diseases: A model of gene mutations and susceptibility polymorphisms for complex psychiatric diseases
8. Diagnosis of Alzheimer's disease: Defining genetic profiles (genotype vs phenotype)
9. Association of genetic risk factors and a novel mutation in the predicted TM2 domain of the presenilin 2 gene in late-onset AD
10. Genetic testing in Alzheimer's disease: APOE genotyping and etiopathogenic factors
11. Genetic neurodegenerative diseases: The human illness and transgenic models
12. The genetics of Alzheimer's disease: Current status and future prospects
13. Mutation-specific functional impairments in distinct tau isoforms of hereditary FTDP-17
14. Twenty-nine missense mutations linked with familial Alzheimer's disease alter the processing of presenilin 1
15. Presenilin-1 mutations in Alzheimer's disease
16. Carriage of apoE ε4 lowers the age of onset of Alzheimer's disease in Northern Ireland
17. The presenilins
18. Presenilin mutations associated with Alzheimer disease cause defective intracellular trafficking of β-catenin, a component of the presenilin protein complex
19. Increased vulnerability of hippocampal neurons to excitotoxic necrosis in presenilin-1 mutant knock-in mice
20. Destabilization of β-catenin by mutations in presenilin-1 potentiates neuronal apoptosis
21. Presenilins: Molecular switches between proteolysis and signal transduction
22. Function and dysfunction of the presenilins
23. Photoactivated γ-secretase inhibitors directed to the active site covalently label presenilin 1
24. Pharmacogenomics and future drug development and delivery
25. Pharmacological properties of piracetam
26. New strategies for Alzheimer's disease treatment: Pleiotropic drugs and multifactorial intervention
27. Effect of CDP-Choline on cognition and immune function in Alzheimer's disease
28. Therapeutic effects of CDP-choline in Alzheimer's disease. Cognition, brain mapping, cerebrovascular hemodynamics, and immune factors
29. Molecular strategies for the first generations of anti-dementia drugs (I)
30. Citicoline improves memory performance in elderly subjects
31. Effects of CDP-choline on cognitive performance, brain bioelectrical activity and brain hemodynamics in Alzheimer's disease patients. A double-blind placebo controlled study
32. Anapsos: Neuroimmunotrophic treatment in Alzheimer disease and neurodegenerarive disorders
33. Diagnosticcriteria and genotyping in Alzheimer's disease
34. A general method for DNA polymorphism identification in genetic assessment and molecular diagnosis
35. Different implications of APOE ε4 in Alzheimer's disease and vascular dementia in the Spanish population
36. Molecular genetics and genotyping in Alzheimer's disease
37. No association between a presenilin 1 polymorphism and Alzheimer disease
38. Aging-dependent large accumulation of point mutations in the human mtDNA control region for replication
39. Apolipoprotein E genotype allele ε4 and response to tacrine in Alzheimer's disease
40. Behavioral changes associated with different apolipoprotein E genotypes in dementia
41. Influence of the APOE genotype on serum ApoE levels in Alzheimer's disease patients
42. Microglia activation induced by factor(s) contained in sera from Alzheimer-related APOE genotypes
43. Tau protein levels in cerebrospinal fluid and apolipoprotein E genotyping in differential diagnosis of dementia
44. Apolipoprotein E ε4 allele in association with global cognitive performance and CSF markers in Alzheimer's disease
45. An experimental model to study the cytotoxic effects induced by β-amyloid, histamine, LPS and serum from Alzheimer patients on cultured rat endothelial cells
46. Transgenic mice with Alzheimer presenilin 1 mutations show accelerated neurodegeneration without amyloid plaque formation
47. The use of single-nucleotide polymorphism maps in pharmacogenomics
48. Pharmacogenomics: Translating functional genomics into rational therapeutics